Lurasidone and Fluvoxamine Combination in Eating Disorders with Comorbid Obsessive-Compulsive Disorder: Preliminary...

Area of Science:

• Psychiatry
• Clinical Psychology
• Pharmacology

Background:

• Anorexia nervosa (AN) and obsessive-compulsive disorder (OCD) share cognitive rigidity, anxiety, and reward processing alterations.
• Limited pharmacological options necessitate exploring novel therapeutic targets.
• Combined serotonergic and dopaminergic modulation is a potential treatment avenue for AN and OCD.

Purpose of the Study:

• To explore the combined efficacy of lurasidone and fluvoxamine versus standard treatments in restrictive AN with comorbid OCD.
• To assess treatment effects on recovery, body uneasiness, and eating disorder psychopathology.
• To investigate the feasibility of Bayesian longitudinal modeling in clinical data.

Main Methods:

• A naturalistic study of 45 female inpatients with restrictive AN and comorbid OCD over six months.
• Comparison of lurasidone + fluvoxamine (n=14) versus heterogeneous SSRI/antipsychotic regimens (n=31).
• Primary outcomes: Recovery Assessment Scale (RAS) and Body Uneasiness Test Global Severity Index (BUT-GSI); Secondary outcomes: EDE-Q and EDI-3; Bayesian repeated-measures ANOVAs used.

Main Results:

• Significant time-related improvements observed in primary outcomes (RAS, BUT-GSI) with moderate-to-strong evidence.
• Secondary and exploratory measures showed weaker or inconsistent trends.
• No significant group-by-time interactions indicating drug-specific effects were found.

Conclusions:

• Findings suggest general rehabilitation effects over time rather than specific drug efficacy in this cohort.
• The study highlights challenges in applying Bayesian longitudinal modeling to incomplete clinical data.
• Future randomized trials with objective endpoints are needed to confirm potential benefits of serotonergic-dopaminergic synergy in the AN-OCD spectrum.